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To celebrate the 20th anniversary of
Molecular Medicine, this special issue
showcases the fields of science influenced by the most cited scientific contributions to the journal over the past two
decades. The authors of these reviews
are leaders in the fields of immunology,
cancer, atherosclerosis, Alzheimer’s disease and diabetes. We asked them to provide updates that highlight the progress
made in the selected fields of research to
which their highly cited Molecular Medicine publication contributed.
Two reviews discuss key elements in
the immune response to tissue injury: one
focuses on the fibrocyte, which acts during the earliest phase of the innate immune response, and the other focuses on
HMGB1, which acts as a later mediator
of inflammation. Richard Bucala reports
on the advances made on the “fibrocyte,”
the unique collagen-producing leukocyte
that he discovered in the 1990s and its
role beyond the original context of

wound repair. The contribution of this
cell type to the pathogenesis of different
fibrosing disorders has led to fibrocytedirected therapies that are currently
being tested in the clinic. Huan Yang and
colleagues provide an overview of
HMGB1, a later mediator of infection
and tissue injury. The authors review its
multiple functions and complex regulation. They conclude with a discussion on
the first two HMGB1-specific antagonists
that are paving the way toward future
therapeutic applications.
A third review by Antonino Nicoletti
and colleagues looks at the adaptive immune response in the context of atherosclerosis. The authors discuss the roles
that proatherogenic and athero-protective
T and B cells play in this disease. They
also highlight the different strategies
used in preclinical studies with an outlook to clinical applications.
Jason A Chesney and Robert A
Mitchell follow the saga of macrophage
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migration inhibitory factor (MIF) from
its discovery through the many studies
that implicate this cytokine in several aspects of cancer biology. They focus in
particular on the role of MIF in tumor
neovascularization, which likely participates in primary and metastatic disease
progression. The advances made in this
field are underscored by the first clinical
trial that has been initiated to test antiMIF therapies.
Jennifer Hardingham and colleagues
cover the circulating tumor cells (CTCs),
another interesting aspect of cancer biology with great implications for clinical
applications. Their discussion of various
technical efforts that have been made to
capture these cells from the patients’
blood, the advances made and the challenges that still remain offer a clear picture of the state of the art of this new approach. These advances will certainly
augment the battery of cancer diagnostic
tools in the clinic in the not too distant
future.
Sho-ichi Yamagishi and colleagues
tackle the role of advanced glycation end
products (AGEs) in diabetes. They describe how the products of reactions occurring between sugars and proteins,
lipids and nucleic acids lead to altered
function and metabolism of these macromolecules with severe consequences in
diabetes and aging-associated disorders.
The authors also discuss the potential
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value of measuring serum levels of AGEs
to evaluate organ damage in diabetes.
Finally, Jochen Walter summarizes the
incredible progress made over the past
two decades in understanding the role of
presenilins in the onset of Alzheimer’s
disease. From the discovery of the gene
mutations in inherited familial forms of
early onset of Alzheimer’s disease, Walter follows the path of discoveries that
leads to the identification of their functions as components of a protease complex responsible for the cleavage of the
amyloid precursor protein, an important
determinant of the pathophysiology of
the disease. He also discusses the hopes
associated with the development of several inhibitors of presenilins and the disappointing results of their use in the
clinic. Dr. Walter concludes with a positive outlook on development of more selective inhibitors of presenilins that
could provide future therapies for Alzheimer’s disease.
We are pleased to offer these engaging
and interesting historical perspectives of
fields that were introduced to the scientific public in our journal and hope that
our readers will enjoy them, too.
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